Orforglipron Cas 2212020-52-3

 

Dab tsi yog Offlofipron?

Txhob Txom Nyem(CAS 2212020-52-3) yog athawj - hauv -}}}- molecule, qhov ncauj receptor agonistTam sim no nyob rau hauv kev tshawb fawb txogKev pham kev tswj, kev poob ceeb, thiab hom 2 ntshav qab zib.
Tsis zoo li cov phooj ywg peptide -} Raws GLP-1 analogs xws liSemaglowsidelossisTirzepatide, Orforglipron yogtsis - peptidic- Ua rau nws ruaj khov, yooj yim dua los tsim, thiab haum rauQhov ncauj Xatsis txhaj tshuaj.

Lub tswv yim no sawv cev rau txoj kev nce qib loj hauvCov metabolic thiab kev rog tshawb fawb, ua kom cov kws tshawb fawb tshawb nrhiav txoj hauv kev tshiab ntawmCov Kev Noj Qab Haus Huv Kev Cai, Kev Siv Zog, thiab qab zib audostasis.

 

 

RauKev Tshawb Nrhiav thiab Kev Loj Hlob, OffloGripron tau pom muaj peev xwm hauv:

• Qhov hnyav -} Tsis Tuag Kev Tshawb Fawb- Txhawb kev lom zem thiab txo cov caloric kom tsawg ntawm GLP-1 txoj kev ua kom muaj zog.
• Cov Kev Cai Tswj Cov Mean- Txhim kho cov kua qaub ua tsaug rau thiab cov tshuaj insulin rhiab hauv cov qauv ua ntej.
• Kev Tshawb Xyuas Zog Hluav Taws Xob- Txhim kho kev siv hluav taws xob thiab lipid metabolism.
• Noj qab neeg tswj cov tshuab- Modulates hypothalamic qhia txog kev tshaib plab thiab satiety.
• Qhov ncauj tsim kev kawm- Cov qauv zoo tagnrho rau kev ntsuas qhov ncauj gpp-1 analog bioavailability thiab ruaj khov.

 

 

 

• Tshuaj Npe:Txhob Txom Nyem
• Tus lej lej: 2212020-52-3
• Molecular Chiv: C₂₁H₂₃N₅O₃
• Molecular hnyav:~ 393.44 g / mol
• Purity:Ntau dua los yog sib npaug rau 98% (hplc txheeb xyuas)
• Daim Ntawv:Dawb lossis tawm - hmoov dawb
• Solubility:Soluble hauv dmo, ethanol, thiab methanol

 

 

Orforglipron yog aXaiv GLP-1 cov lus rov ua dua tshiab, khi rau lub receptor thiab mimicking kev ua ntawm ntuj glp - 1 (glucagon-zoo li peptide-1).

• Qhov kev ua kom tau txais cov kev ua haujlwm no ua rau muaj kev nkag mus hauv qhov ntawd.
• Txhim khoInsulin kev zaisHauv kev teb rau cov piam thaj
• TxhawbGlucagon Tshaj Tawm
• Ua qeebPais plab nchuav, coj mus rau lub siab satiety
• Txo qisqab los noj mov thiab caloric nkag

Tsis zoo li peptide glp-1 yeeb tshuaj, orforlolipron yogtsis - degradable los ntawm zom cov enzymes, tso caiQhov ncauj dosingthiabKev ua kom zoo sib xws.

 

 

Sib xyaw	Ntaus	Kev ua nom	Cov Phiaj xwm Tseem Ceeb	Sau ntawv
Txhob Txom Nyem	Tsis - peptide glp-1 agonist	Zaj lus	Ruaj khov, yooj yim, nqi -} txuag	Tshiab tiam
Semaglowside	Peptide GLP-1 agonist	Kev txhaj tshuaj lossis ncauj	Muaj zog, chaw kuaj mob	Yuav tsum tau ua kom muaj zog
Tirzepatide	Dual GIP / GLP-1 Peptide	Kev txhaj tshuaj	Dual receptor kev ua si	Kev mob nkaus xwb
Likaglutide	Peptide GLP-1 agonist	Kev txhaj tshuaj	Ntev - ua yeeb yam peptide	Tsawg qhov ncauj ruaj khov

Orforglipron sawv tawmRaws li atsis - peptidic molecule, muaj peev xwm hloov pauvKev pham thiab ntshav qab zib tshawb nrhiavlos ntawm kev hloov kho me nyuam thiab metabolic durability.

 

 

Cia kub:-20℃(lub sij hawm ntev)

Tiv thaiv los ntawm:Lub teeb, noo noo, thiab cua sov

Txee Lub Neej:Ntau dua los yog sib npaug rau 3 xyoo raws li kev cia khoom tsim nyog

Reconstource:Dissolve hauv DMO lossis ethanol rau kev tshawb fawb siv

Nco tseg:RauKuaj cov kev tshawb fawb nkaus xwbCov. Tsis tau pom zoo rau tib neeg lossis kev siv tsiaj txhu siv.

 

 

Kov nrog txheem kuaj PPE (looj tes looj hnab looj tes, hnab looj tes, lub tsho ntev).

Tsis txhob nqus tau pa, noj, lossis tiv tauj nrog daim tawv nqaij.

Muab cov txheej txheem ntawm raws li kev coj noj coj ua Biosafety.

 

 

Q1: Dab tsi ua rau lossis lossis cov cim tshwj xeeb?
A: Nws yog tusthawj thiab nquag ua haujlwm, tsis {{{0} peptide GPP-1 Cov Lus Qhia Tawm, Tshem tawm cov kev xav tau kev txhaj tshuaj thiab txhim kho cov qauv versulation versatility.

Q2: Nws txawv li cas ntawm cov semaglutide lossis tirzepatide?
A: Offlopipron yog- molecule, tsis peptide - Raws li, muab nws ntau dua cov tshuaj ruaj khov thiab qhov ncauj bioavailability.

Q3: Muaj peev xwm lossis siv tau los nrog lwm tus neeg sawv cev metabolic?
A: Kev tshawb fawb kev tshawb fawb feem ntau ua ke GLP-1 agonists nrogAMPK cov neeg ua haujlwmlossisSglt2 inhibitorsTxhawm rau tshawb cov kev ua haujlwm metabicistic.

Q4: yog los yog los yog lossis muaj nyob rau hauv ntau?
A: yog -}} peb muabloj thiab me - kom muaj nuj nqis los sisRau R & D Daim Ntawv Thov Thoob Ntiaj Teb, nrog puv Coa thiab MSDS cov ntaub ntawv.

 

 

Orforglipron (CAS 2212020-52-3)sawv cev rauYav Tom Ntej ntawm GLP-1 Kev Tshawb Fawb Kev Tiv Thaiv- me me, ruaj khov, ruaj khov, qhov ncauj ua kom pom kev pom rau hauvRog Rog, Noj Qab Haus Huv, thiab Cov Kev Cai Tswj Metabolic.
Rau cov chaw soj ntsuam tshawb xyuastsis - peptide metabolic modulators, Orforglipron yog qhov kev xaiv zoo tshaj plaws vim nwsQhov ncauj ntawm kev ua si, kev ruaj khov, thiab glp-1 receptor tshwj xeeb.

 

 

Siab purity (ntau dua los yog sib npaug rau 98%)xyuas los ntawm HPLC thiab MS

COA & MSDS muabNrog txhua pob

Ntiaj Teb ShippingNrog kub -} tswj ntim

Txog thiab kev cai muaj nuj nqisyuav tau

Kev Txhawb Nqa Cov KwsRau cov kev tshawb fawb thiab GLP-1 txoj kev tshawb fawb

Tus nqi sib twRau cov tsev kawm qib siab, Biotech, thiab R & D cov tuam txhab

 

 

LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS LOSSIS Lub cev hnyav-poob peptide, lossis tshawb fawb lossis tshawb fawb txog kev rog.

 

 

YuavOrforglipron (CAS 2212020-52-3)- -}} tiamQhov ncauj GP-1 tus neeg rov ua dua tshiabrauCov metabolic thiab kev rog tshawb fawbCov. {- purity}- peptide hnyav rau siab heev-}}}}}}}}}}}}}}}}}}}}}}}}

 

 

 

 

 

 

 

Cim npe nrov: Orforglipron Cas 2212020-52-3, Tuam Tshoj lossis Tuam Tshoj Orforgipron Cas 2212020-52-3 tus neeg muag khoom